▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3707 by analyst upside · 2026-06-27
AMGN
Amgen Inc.
Healthcare · Market Cap $193B · P/E 24.6x
ANALYST PRICE TARGET
-1.6%
implied upside to consensus target
Current Price $358.33
Consensus Target $352.77
Bull Target $427.0
Bear Target $200.0
Analysts Covering 30
ANALYST CONSENSUS — HOLD
Strong Buy
4
Buy
8
Hold
16
Sell
2
52-Week Low $269.77
52-Week High $391.29
YTD Return +11.0%
FUNDAMENTALS
Market Cap $193B
P/E Ratio (TTM) 24.6x
Forward P/E 15.3x
EPS (TTM) $14.58
PEG Ratio 2.32
Dividend Yield 2.86%
Revenue (TTM) $37.2B
Profit Margin 21.0%
52-WEEK RANGE
52-Week Low $269.77
52-Week High $391.29
Current Price $358.33
Bear Target $200.0
Bull Target $427.0
● Now $358.33 ● Target $352.77
TRADING DATA
Avg Volume 2.8M
YTD Return +11.0%
Analyst Count 30
Consensus Hold
Upside to Target -1.6%
Last Updated 2026-06-27

ANALYST SUMMARY

Amgen Inc. (AMGN) is currently trading at $358.33 with a Wall Street consensus price target of $352.77, which is 1.6% below the current price over the next 12 months. 30 analysts currently cover AMGN, with a consensus rating of Hold — 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $427.0, while the most cautious has a target of $200.0.

AMGN operates in the Healthcare sector with a market capitalisation of $193B. The stock is up 11.0% year-to-date and is currently trading near the upper end of its 52-week range of $269.77 – $391.29.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

NVO -2.5%
Novo Nordisk A/S
$213B · P/E 11.4x · Hold
TMO +16.8%
Thermo Fisher Scientific Inc.
$191B · P/E 28.2x · Buy
NONOF +22.5%
Novo Nordisk A/S
$192B · P/E 10.2x · Hold
ABT +23.8%
Abbott Laboratories
$164B · P/E 26.4x · Buy
GILD +23.2%
Gilead Sciences, Inc.
$159B · P/E 17.4x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for AMGN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Mizuho — Reiterated
Neutral → Neutral 2026-06-16 Building track record
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-06-10 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-05-14 14% win rate (7 calls)
Guggenheim — Reiterated
Neutral → Neutral 2026-05-04 62% win rate (8 calls)
Truist Securities — Reiterated
Hold → Hold 2026-05-01 Building track record
Canaccord Genuity ● Initiated
Hold 2026-04-21 Building track record
UBS — Reiterated
Buy → Buy 2026-04-13 33% win rate (6 calls)
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-04-10 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →